NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
Source: NHS Networks - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | National Institute for Health and Clinical Excelle | UK Health